KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Ratio: 2018-2024

Historic Equity Ratio for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to 1.13.

  • Esperion Therapeutics' Equity Ratio fell 5.21% to 1.24 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.24, marking a year-over-year decrease of 5.21%. This contributed to the annual value of 1.13 for FY2024, which is 48.86% up from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Equity Ratio is 1.13, which was up 48.86% from 2.21 recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Equity Ratio ranged from a high of 0.27 in FY2020 and a low of 2.21 during FY2023.
  • Over the past 3 years, Esperion Therapeutics' median Equity Ratio value was 1.31 (recorded in 2022), while the average stood at 1.55.
  • Per our database at Business Quant, Esperion Therapeutics' Equity Ratio plummeted by 392.52% in 2020 and then surged by 48.86% in 2024.
  • Esperion Therapeutics' Equity Ratio (MRY) stood at 0.27 in 2020, then plummeted by 89.65% to 0.52 in 2021, then plummeted by 153.02% to 1.31 in 2022, then tumbled by 69.30% to 2.21 in 2023, then soared by 48.86% to 1.13 in 2024.
  • Its Equity Ratio was 1.13 in FY2024, compared to 2.21 in FY2023 and 1.31 in FY2022.